Evidence map›Paper›PMID 37809081›Full record

ArticleFrontiers in immunology2023

SARS-CoV-2 spike antigen-specific B cell and antibody responses in pre-vaccination period COVID-19 convalescent males and females with or without post-covid condition.

Marc-André Limoges, Akouavi Julite Irmine Quenum, Mohammad Mobarak Hussain Chowdhury, Fjolla Rexhepi, Mozhdeh Namvarpour, Sara Ali Akbari, Christine Rioux-Perreault, Madhuparna Nandi, Jean-François Lucier, Samuel Lemaire-Paquette and 10 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. BMJ open · 2025
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Marc-André LimogesDepartment of Immunology and Cell Biology, Faculty of Medicine and Health Sciences, Sherbrooke, QC, Canada.
Akouavi Julite Irmine QuenumDepartment of Immunology and Cell Biology, Faculty of Medicine and Health Sciences, Sherbrooke, QC, Canada.
Mohammad Mobarak Hussain ChowdhuryDepartment of Immunology and Cell Biology, Faculty of Medicine and Health Sciences, Sherbrooke, QC, Canada.
Fjolla RexhepiDepartment of Immunology and Cell Biology, Faculty of Medicine and Health Sciences, Sherbrooke, QC, Canada.
Mozhdeh NamvarpourDepartment of Immunology and Cell Biology, Faculty of Medicine and Health Sciences, Sherbrooke, QC, Canada.
Sara Ali AkbariDepartment of Immunology and Cell Biology, Faculty of Medicine and Health Sciences, Sherbrooke, QC, Canada.
Christine Rioux-PerreaultDepartment of Microbiology and Infectious Diseases, Faculty of Medicine and Health Sciences, Sherbrooke, QC, Canada.
Madhuparna NandiDepartment of Immunology and Cell Biology, Faculty of Medicine and Health Sciences, Sherbrooke, QC, Canada.
Jean-François LucierDepartment of Biology, Faculty of Science, University of Sherbrooke, Sherbrooke, QC, Canada.
Samuel Lemaire-PaquetteUnité de Recherche Clinique et épidémiologique, Centre de Recherche du CHUS, Sherbrooke, QC, Canada.
Lakshmanane PremkumarDepartment of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Yves DurocherMammalian Cell Expression, Human Health Therapeutics Research Centre, National Research Council Canada, Montreal, QC, Canada.
André CantinDepartments of Medicine, Faculty of Medicine and Health Sciences, Sherbrooke, QC, Canada.
Simon LévesqueDepartment of Microbiology and Infectious Diseases, Faculty of Medicine and Health Sciences, Sherbrooke, QC, Canada.
Isabelle J DionneFaculty of Physical Activity Sciences, University of Sherbrooke, Sherbrooke, QC, Canada.
Alfredo MenendezDepartment of Microbiology and Infectious Diseases, Faculty of Medicine and Health Sciences, Sherbrooke, QC, Canada.
Subburaj IlangumaranDepartment of Immunology and Cell Biology, Faculty of Medicine and Health Sciences, Sherbrooke, QC, Canada.
Hugues Allard-ChamardDepartment of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Alain PichéDepartment of Microbiology and Infectious Diseases, Faculty of Medicine and Health Sciences, Sherbrooke, QC, Canada.
Sheela RamanathanDepartment of Immunology and Cell Biology, Faculty of Medicine and Health Sciences, Sherbrooke, QC, Canada.

Funding

CIHR GA4-177773
6 · The paper itself

Abstract

Background: Following SARS-CoV-2 infection a significant proportion of convalescent individuals develop the post-COVID condition (PCC) that is characterized by wide spectrum of symptoms encompassing various organs. Even though the underlying pathophysiology of PCC is not known, detection of viral transcripts and antigens in tissues other than lungs raise the possibility that PCC may be a consequence of aberrant immune response to the viral antigens. To test this hypothesis, we evaluated B cell and antibody responses to the SARS-CoV-2 antigens in PCC patients who experienced mild COVID-19 disease during the pre-vaccination period of COVID-19 pandemic. Methods: The study subjects included unvaccinated male and female subjects who developed PCC or not (No-PCC) after clearing RT-PCR confirmed mild COVID-19 infection. SARS-CoV-2 D614G and omicron RBD specific B cell subsets in peripheral circulation were assessed by flow cytometry. IgG, IgG3 and IgA antibody titers toward RBD, spike and nucleocapsid antigens in the plasma were evaluated by ELISA. Results: The frequency of the B cells specific to D614G-RBD were comparable in convalescent groups with and without PCC in both males and females. Notably, in females with PCC, the anti-D614G RBD specific double negative (IgD Conclusions: The antibody responses to the spike protein, but not the anti-RBD B cell responses diverge between convalescent males and females who develop PCC. Our findings also suggest that sex-related factors may also be involved in the development of PCC via modulating antibody responses to the SARS-CoV-2 antigens.

Indexed as

COVID-19Antibody FormationFemaleHumansImmunoglobulin GMalePandemicsPost-Acute COVID-19 SyndromeSARS-CoV-2Immunoglobulin Ganti-RBD antibody titerlong covidpost covid condition (PCC)RBD specific B cellsSARS-CoV-2 infection

Identifiers

PMID37809081
PMCPMC10551145

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.